WO1997002342A1 - Anticorps recombines tires d'une banque de presentation de phage, contre un complexe peptide-cmh - Google Patents

Anticorps recombines tires d'une banque de presentation de phage, contre un complexe peptide-cmh Download PDF

Info

Publication number
WO1997002342A1
WO1997002342A1 PCT/DK1996/000296 DK9600296W WO9702342A1 WO 1997002342 A1 WO1997002342 A1 WO 1997002342A1 DK 9600296 W DK9600296 W DK 9600296W WO 9702342 A1 WO9702342 A1 WO 9702342A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
peptide
mhc complex
mhc
antibody fragment
Prior art date
Application number
PCT/DK1996/000296
Other languages
English (en)
Inventor
Peter Sejer Andersen
Søren Buus
Jan Engberg
Lars Fugger
Anette Stryhn
Original Assignee
Københavns Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet filed Critical Københavns Universitet
Priority to JP9504728A priority Critical patent/JPH11510375A/ja
Priority to AU63535/96A priority patent/AU6353596A/en
Priority to EP96922777A priority patent/EP0835306A1/fr
Publication of WO1997002342A1 publication Critical patent/WO1997002342A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to recombinant antibodies and fragments of antibodies with the antigen-specific, MHC-restricted specifi ⁇ city of T cells.
  • T and B cells represent two fundamentally different recog ⁇ nition modes of the specific immune system.
  • T cells are educated to recognize antigenic peptides presented in association with self-mole ⁇ cules of the major histocompatibility complex (MHC) on the surface of antigen presenting cells.
  • MHC major histocompatibility complex
  • B cells are not educated to be self-MHC restricted and B cell receptors (antibodies) , whether soluble or in membrane bound form, recognize three-dimensional target structures.
  • T cells are faced with the same problem of recognizing a ligand dominated by self-MHC and an entire organ has been devoted to educating T cells. Positive and negative selection processes delete the vast majority of maturing thymocytes and only a small minority enters the circulation as mature non- auto-reactive, yet self-MHC-restricted, T cells (von Boehmer et al. , 1989) .
  • phage display antibody fragments isolated from immunization based libraries in general have thousand fold higher affinities than those isolated from naive non-immunized libraries (Marks et al. , 1991; Bye et al., 1992; Hoogenboom and Winter, 1992).
  • WO 95/15982 relates to a method for generating an antibody specific for an immu- norecessive epitope using the phage display technology.
  • WO 91/12332 discloses restricted monoclo ⁇ nal antibodies characterized by their ability to specifically recognize a complex consisting of a peptide which is cha ⁇ racteristic of a pathogenic agent antigen or a cell derange ⁇ ment, and a Major Histocompatibility Complex (MHC) molecule, the antibodies being restricted by not having the ability to recognize said peptide combined with a non peptide specific haplotype MHC molecule.
  • MHC Major Histocompatibility Complex
  • the present invention provides a method to generate antibody and antibody fragments recognizing specific, predetermined peptide-MHC complexes by use of the phage display technology.
  • the speed and feasibility of this technique make it realistic to produce antibodies and fragments of antibodies to a varie- ty of specific peptide-MHC complexes which are contemplated to be useful in studying MHC-restricted T cell recognition and lead to novel approaches in diagnostics and immunotherapy.
  • the invention encompasses recom ⁇ binant antigen-specific MHC-restricted antibodies as such.
  • One important aspect of the invention is a method to generate recombinant antibody or antibody fragments recognizing a pre ⁇ determined peptide-MHC complex by taking advantage of the high selection power of the phage display technology.
  • the invention relates to a method of producing an antibody or an antibody fragment specifically recognizing a peptide-MHC complex, the method comprising
  • nucleic acid is meant a polynucleotide of high molecular weight which can occur as either DNA or RNA and may be either single-stranded or double-stranded.
  • the nucleic acid fragment (s) can be obtained either from “teraphage” libraries or from antibody libraries from immunized animals as detailed below.
  • a teraphage library is meant a library comprising a very large number of human antibody gene fragments thus providing a high likelihood that a gene fragment encoding an antibody or antibody fragment of interest is present; examples of such very large libraries are described e.g. in Waterhouse, P.G. et al., 1993, Griffiths, A. et al., 1994.
  • This approach will be very useful if treatment of individual patients with one or more antibodies which are specifically reacting with MHC- peptide complexes present within said patient is to be acom- plished since it will be possible within a reasonable time to generate specific antibodies directed against a preselected MHC-peptide complex which may be unique for said individual.
  • nucleic acids encoding an antibody or antibody fragment are amplified and producing a phage library expressing said nucleic acid frag ⁇ ments
  • a simi ⁇ lar approach as outlined in the examples or modified by use of the teraphage technique described in Waterhouse, G.P. et al. can be used with respect to other antibody fragments or entire antibodies.
  • the use of the phage display technique is preferred, it is contemplated that recombinant peptide-MHC specific antibodies may also be prepared by use of alternative methods, e.g. single chain Fv antibody frag- ment display on plasmids (Cull et al. , 1992) or cells (Francisco et al. , 1993).
  • antibodies are glycoproteins which exhibit binding specificity to a specific antigen.
  • Antibodies are usually heterotetrameric glycopro ⁇ teins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent di- sulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin iso- types. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable domain (V H ) at one end followed by a number of constant domains.
  • V H variable domain
  • Each light chain has a variable domain at one end (V L ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains.
  • Papain digestion of antibodies produces two identical antigen binding fragments, called “Fab” fragments, each with a single antigen binding site, and a residual “Fc” fragment, whose name reflects its ability to crystallize readily.
  • Pepsin treatment yields an F(ab') 2 fragment that has two antigen combining sites and is still capable of cross-linking anti ⁇ gen.
  • Fv is the minimum antibody fragment which contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the V H -V L dimer.
  • the six CDRs confer antigen binding specificity to the antibody.
  • a single variable domain or half of an Fv comprising only three CDRs specific for an antigen
  • i.e. an scFv has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
  • the Fab fragment also contains the constant domain of the light chain and the first constant domain (CHI) of the heavy chain.
  • Fab' fragments differ from Fab fragments by the addition of a few residues at the car ⁇ boxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region.
  • F(ab') anti- body fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them.
  • the "light chains" of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa ( K ) and lambda ( ⁇ ) , based on the amino acid sequences of their constant domains.
  • K kappa
  • ⁇ lambda
  • anti ⁇ bodies can be assigned to different classes of which there are five major classes: IgA, IgD, IgE, IgG and IgM.
  • IgA, IgD, IgE, IgG and IgM Several of these may be further divided into subclasses (isotypes) , e.g., IgG-l, IgG-2, IgG-3, and lgG-4; lgA-1 and IgA-2.
  • antibody and antibody fragments is used in the present specification and claims in the broadest sense and specifically covers single monoclonal antibodies as well as antibody fragments (e.g., Fab, Fab', F(ab') 2 , Fv and scFv) , as long as they specifically recognize a peptide-MHC complex.
  • the invention thus relates to methods according to the inven- tion wherein the antibody fragment is selected from the group consisting of Fab, Fab', F(ab') 2 , Fv, scFv and other antigen- binding subsequences of an antibody.
  • Complexes of the anti ⁇ bodies or fragments of antibodies of the invention, such as IgM or IgG complexes are also within the scope of the inven ⁇ tion.
  • monoclonal antibody refers to an antibody obtained from a population of substantially homo ⁇ geneous antibodies, i.e., the individual antibodies compris- ing the population are identical except for possible natural ⁇ ly occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, each monoclonal antibody is directed against a single determinant on the anti- gen.
  • the monoclonal antibodies herein specifically include "chime ⁇ ric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding se ⁇ quences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric antibodies or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of anti ⁇ bodies, e.g. scFv) which contain minimal sequence derived from non-human antibody.
  • humanized anti ⁇ bodies are human antibodies (recepient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • donor antibody such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • Fv framework residues of the human antibody are replaced by corresponding non-human residues.
  • an antibody or a fragment of an antibody specifically recognizing a peptide-MHC complex has been produced by the method of the invention
  • the person skilled in the art will be able to prepare appropriate analogues of said antibody or antibody fragment, e.g. "humanized” antibodies comprising an antigen-binding subsequence prepared by the method of the invention and FR regions of e.g. a human antibody consensus sequence as well as at least a portion of an antibody con ⁇ stant region, if appropriate.
  • humanized antibodies comprising an antigen-binding subsequence prepared by the method of the invention and FR regions of e.g. a human antibody consensus sequence as well as at least a portion of an antibody con ⁇ stant region, if appropriate.
  • FR regions of e.g. a human antibody consensus sequence as well as at least a portion of an antibody con ⁇ stant region
  • HLA-A, HLA-B and HLA-C loci - constitute the core of the socalled classic HLA class I genes.
  • These genes are highly polymor ⁇ phic, are expressed on virtually all nucleated cells, and are known, at least in the case of HLA-A and -B, to restrict T- cell responses to intracellular antigens.
  • a total of 125 alleles of the HLA-A, -B and -C genes have been offi ⁇ cially acknowledged by the WHO Nomenclature Committee for Factors of the HLA System.
  • an HLA class I molecule requires the presence of peptides that bind that specific HLA allele.
  • the peptides are provided by a process termed antigen processing. All the peptides investigated con- tain at least two "anchor positions" in which only a single amino acid or a few amino acids with closely related side chains have been detected. Invariably, one of these anchors was the C-terminal position. In the natural environment, the peptide generally has a length of 8 to 10 residues. (Madden, D.R. , 1995) .
  • HLA class II molecules are structurally highly related to class I molecules; this relatedness includes the domain organization and probably also the antigen-binding site. Class II molecules are predominantly involved in the inter- action between specific cell types that regulate immune responses, among these B cells, activated T cells, dendritic cells, and cells of the myelomonocytoid lineage (macrophages) . Three isotypes, called DR, DQ, and DP, are distinguished among the class II proteins.
  • peptide comprises both short peptides with a length of at least two amino acid residues and at most 10 amino acid residues and oligopeptides (11-100 amino acid residues) as well as pro ⁇ teins (the functional entity comprising at least one peptide, oligopeptide, or polypeptide which may be chemically modified by being glycosylated, by being lipidated, or by comprising prosthetic groups) .
  • the definition of peptides also includes native forms of peptides/proteins in animals including humans as well as recombinant proteins or peptides in any type of expression vectors transforming any kind of host, and also chemically synthesized peptides.
  • an MHC molecule is explained above.
  • a peptide-MHC complex means a peptide which is capable of binding to a particular MHC molecule thereby establishing a specific peptide-MHC complex. It will be evident from the above that it is possible to produce numerous different anti ⁇ bodies by the method of the invention by making appropriate variations with respect to the particular peptide and MHC molecule used to generate or select the antibody in question.
  • the term "specifically recognizing a peptide-MHC complex” means that the antibody is capable of binding to the peptide- MHC complex with an equilibrium dissociation constant, K D in the range of IO "7 to 10 "10 M.
  • the equilibrium dissociation constant, K D of an antibody or fragment thereof produced by the method of the invention may be determined by any appro- priate method as selected by the person skilled in the art, e.g. by the method outlined in Example 3, wherein the kinetic binding analysis of pSAN 13.4.1 by use of surface plasmon resonance is described in detail.
  • An important step in the method of the invention is the se ⁇ lection of a phage expressing an antibody or antibody frag ⁇ ment specifically recognizing a peptide-MHC complex.
  • this selection is performed by incubating cells expressing the peptide-MHC complex with the phage library and/or incubating the phage library with beads to which the peptide-MHC complex is bound.
  • the selection is performed by panning a li ⁇ brary of phages expressing antibody or antibody fragments on alternating matrices carrying the peptide-MHC complex as the common denominator.
  • the alter ⁇ nating matrices are cells expressing the peptide-MHC complex and beads to which the peptide-MHC complex is bound.
  • two different plastic surfaces such as immunotubes (NUNC) or latex beads may be used as matrices coated with the selected MHC/peptide complex.
  • NUNC immunotubes
  • bound phages are eluted and amplified in a cell such as E. coli after each panning round and optionally analyzed by FACS for binding to cells expressing the MHC molecule in complex with said peptide.
  • this enrichment is also an important factor for the success of the immunization as well as the subsequent pannings and thus, it may be advantageous to further enrich the MHC molecules e.g. up to about 90%, about 95% or even about 98% or about 99%. i.e. substantially 100% specific peptide-MHC loading. If the immunization step is avoided by use of the teraphage technique, it is contem ⁇ plated that it is even more important for a successive selec ⁇ tion procedure that purified MHC molecules which have been enriched for one particular peptide is used. However, it is not unlikely that beneficial results may also be obtained with less enrichment of selected MHC molecules with the desired peptide, e.g. about 20%, 30%, 50%, 66% or 75%.
  • the method of the invention further comprises a step wherein the nucleic acids encoding an antibody or antibody fragment are introduced into an appropriate cell so as to produce an antibody or an antibody fragment specifically recognizing the desired peptide-MHC complex.
  • the cell can be selected from the group consisting of a microorganism such as a bacterium, e.g. Escherichia coli , a yeast, a protozoan, and a cell derived from a multicellular organism such as a fungus, an insect cell, a plant cell, a mammalian cell or a cell line.
  • the DNA encoding the ScFv fragment of the antibody could be introduced into embryonic stem cells to generate transgenic animals producing the antibody fragment under control of tissue specific promoters (Logan, 1993) .
  • the DNA fragment comprising the nucleic acids encoding the antibody or frag ⁇ ment of antibody is introduced into the organism or cell either directly or by means of a suitable vector.
  • the cells producing the desired antibodies or fragments of antibodies are then selected based on levels of productivity under con ⁇ ditions suitable for the vector and the cell.
  • the selected cells are grown further and form a very important and conti ⁇ nuous source of the desired antibodies or antibody fragments.
  • the DNA fragment encoding an anti ⁇ body or antibody fragment can be cloned, and the nucleotide sequence determined. If desired, the person skilled in the art can then by using conventional techniques such as e.g.
  • the selection of these novel antibodies requires the use of a selection procedure essentially as outlined with respect to the original antibody. In a similar manner, it will be poss ⁇ ible to prepare genetically engineered antibodies with a binding specificity towards another peptide-MHC complex, if the selection procedure is appropriately amended.
  • the invention relates to a method wherein the nucleic acids encoding said antibody fragment is encoded by the plasmid pSAN 13.4.1 which has been deposited on 28 June 1995 with the collection of Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM) under the acces ⁇ sion number DSM 10070 in accordance with the provisions of the Budapest Treaty.
  • DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
  • One important embodiment of the invention thus relates to a DNA fragment or an analogue or subsequence thereof encoding a restricted antibody or antibody fragment of the invention contained within an expression vector which is capable of replicating in a host organism or a cell line.
  • the vector may in particular be a plasmid, a phage, a cosmid, a mini-chro ⁇ mosome or a virus.
  • the vector may be a vector which, when introduced in a host cell, is integrated into the host cell genome.
  • the invention relates to an antibody or antibody fragment specifically recognizing a peptide-MHC com ⁇ plex prepared by the method of the invention.
  • the invention encompasses a non-glycosylated antibody or anti- body fragment specifically recognizing a peptide-MHC complex.
  • Such an antibody or antibody fragment may be produced when the plasmid encoding the antibody or antibody fragment is expressed in E. coli .
  • an antibody or antibody fragment according to the invention conjugated to a pharma ⁇ ceutical agent, such as a pharmaceutical agent selected from the group consisting of antibiotic, cytotoxic and antineoplastic agents.
  • a pharma ⁇ ceutical agent such as a pharmaceutical agent selected from the group consisting of antibiotic, cytotoxic and antineoplastic agents.
  • the antibody or anti- body fragment may be conjugated to a superantigen, which is capable of activating T lymphocytes, such as the bacterial superantigen staphylococcal enterotoxin A (SEA) (Dohlstein M. et al., 1994).
  • SEA staphylococcal enterotoxin A
  • Superantigenicity may be conveyed on cells recognized by the antibody and thereby evoke T cells to suppress tumour growth or autoimmune disease as described in further detail in the following.
  • the antibody or antibody fragment is conjugated to a polymerized carbohydrate, which is capable of activating complement and thereby targeting desired cells expressing the peptide-MHC complex recognized by
  • the antibody is a bifunctional antibody which contains one combining site specifically recognizing a specific peptide-MHC complex and another site specifically recognizing an epitope of another antigen, e.g. an epitope on a cytotoxic T-cell, or a pharma ⁇ ceutical agent.
  • the bifunctional antibody may be produced by hybrids between two monoclonal cell lines producing the two relevant anti ⁇ bodies or may be produced by chemically linking fragments of the two antibodies.
  • combining site is understood to mean the antigen recognition structure in the variable region of the antibody molecule.
  • Bifunctional antibodies make possible special pro ⁇ cedures for detecting the peptide-MHC complex in a sample and for targeting a pharmaceutical agent, a biologically active molecule or another antigen to the site where the reagent has the greatest effect.
  • the other antigen with which the bifunctional antibody is reactive is an effector cell such as a differentiation antigen of cytotoxic T-cells (cf. Staerz et al. , 1985; van Ravenswaay-Claasen et al. , 1993; Fanger et al. , 1989).
  • the pharmaceutical agents with which the hybrid antibody may be reactive is preferably selected from cytotoxic, antibiotic or antineoplastic agents (cf. Coiler and Kaplan, 1984) .
  • T cell responses may be devised by the use of antibodies and fragments of antibodies of the invention.
  • Intracellularly located viruses, bacteria, or parasites are normally presented by MHC class I and recog ⁇ nized by cytotoxic T cells rather than by antibodies.
  • Anti ⁇ bodies that are specific for peptides presented in complex with MHC class I molecules could be conjugated to toxins and used to mimic T cell responses eradicating e.g. virus infected cells where T cells had failed to do so.
  • An example of a disease where a such approach could be useful is HIV.
  • These antibodies can also direct complement lysis against T cell ligands suggesting other novel approaches to immunotherapy.
  • the idiotypic (antigen binding) structure of an antibody is antigenic and can thus give rise to specific antibodies directed against the idiotypic structure.
  • the antibodies raised against the idiotype are called anti-idiotypic anti ⁇ bodies.
  • Such antibodies may mimic the structure of the ori- ginal antigen and therefore may function as the original anti ⁇ gen.
  • Such antibodies may be able to substitute the original antigen for a part or all of the functions, usability and properties.
  • an anti-idiotypic antibody which is directed against an antibody fragment according to the inventon.
  • the antibody may also be an anti-anti-idiotypic antibody di ⁇ rected against an anti-idiotypic antibody which is an anti ⁇ body directed against the site of an antibody which is reac ⁇ tive with the epitope on the antigen.
  • the anti-idiotypic anti- body may be prepared by a methods well known to the person skilled in the art. Also anti-anti-idiotypic antibodies which are directed against the anti-idiotypic antibody described above are within the scope of the invention.
  • the invention also provides a pharmaceutical composi- tion for combatting intracellularly located pathogens selected from the group consisting of viruses, bacteria and parasites, said composition comprising an antibody or frag ⁇ ment according to the invention and a pharmaceutically accep ⁇ table excipient.
  • the pharmaceutical compositions described above may comprise a monoclonal antibody or a mixture of monoclonal antibodies specifically recognizing the peptide- MHC complex, or a mixture of antibodies recognizing different peptide-MHC complexes.
  • HLA class I and II molecules function by binding antigenic peptides and present- ing them to CD8+ and CD4+ T cells, respectively. It is there ⁇ fore very likely that certain HLA alleles confer susceptibi ⁇ lity to autoimmune diseases at the molecular level by binding specific antigenic peptides that other alleles do not bind. For further information see: Fugger L. et al., 1995.
  • anti-peptide-MHC antibodies may block inappro ⁇ priate immune T cells responses such as those leading to auto immunity (Aharoni et al. , 1991).
  • MHC being a significant risk factor in many autoimmune diseases indicates the existence of a single or a few diseases initiating self-MHC restricted autoantigen. If so, antibody fragments directed against such ligands could prove powerful inhibitors of in vivo autoimmune T cell responses.
  • blocking antibodies would require knowledge about the disease inducing T cell epitope and the restricting MHC molecule, requirements that may be fulfilled in the future (Tisch et al., 1993; Kaufman et al., 1993; Michaelsson et al., 1994; Wurcherpfennig and Strominger, 1995).
  • the invention thus relates to a pharmaceutical composition for blocking an inappropriate T cell response comprising an antibody or antibody fragment according to the invention and a pharmaceutically acceptable excipient.
  • the invention relates to a pharma ⁇ ceutical composition for prevention after establishment of being in a high risk group of developing a malignant tumour, treatment or prevention of a relapse of a malignant tumour, said composition comprising an antibody or antibody fragment according to the invention and a pharmaceutically acceptable excipient.
  • the pharmaceutical compositions may be formulated by methods well known within the art.
  • Another aspect of the invention relates to a pharmaceutical composition for treatment or prevention of a relapse of an autoimmune disase, said composition comprising an antibody or antibody fragment according to the invention and a pharmaceu ⁇ tically acceptable excipient.
  • the invention relates to the use of a pharmaceutical composition according to the invention for the prevention or treatment of a disease selected from the group consisting of HLA class I associated diseases (ankylosing spondylitis, Reiter disease, psoriatic spondylitis, idio- pathic hemochromatosis, psoriasis vulgaris and Behcet dis ⁇ ease) and HLA class II associated diseases (rheumatoid ar ⁇ thritis, pauciarticular juvenile rheumatoid arthritis, sys ⁇ temic lupus erythematosus, Sj ⁇ gren disease, IDDM, Addison disease, Graves disease, Hashimoto disease, celiac disease, primary biliary cirrhosis, pemphigus vulgaris, epidermolysis bullosa acquisita, Hodgkin disease, cervical squamous cell carcinoma, multiple sclerosis, optic neuritis, narcolepsi, myas
  • Antibodies directed against specific peptide-MHC combinations may be used to detect the presence of such peptide-MHC com ⁇ plexes on the surface of cells in the body.
  • the requirements for the generation of peptide-MHC complexes are that the cell express the MHC in question and that it can generate the peptide in question. The former depends on the cell type and whether the cell has been stimulated with various cytokines. In general, all somatic cells express MHC class I, whereas a more restricted set of immune cells (dendritic cells, B cells etc) express MHC class II. As an example of stimulated MHC expression one could mention the 7-interferon induced MHC class II expression on macrophages.
  • antigen pro ⁇ cessing generates short peptide fragments from all intracellular proteins including mutated self-proteins and protein antigens derived from infectious agents.
  • the MHC molecule binds and presents peptides derived from all self and foreign protein antigens.
  • T cells The normal function of T cells is to scrutinize the identity of the peptide-MHC complexes presented by cells in the body for the purpose of attacking foreign combinations and ignor ⁇ ing self combinations.
  • An antibody which can recognize the identity of peptide-MHC complexes would be able to make the same self-non-self distinction.
  • Such an antibody would have several advantages compared to T cells some of which are: antibodies are easier to prepare and label, they are easier to transport and store, they are thought to have higher affi ⁇ nities allowing more sensitive and robust assay, they can be tested in various non-physiological buffers.
  • peptide-MHC specific antibodies it would be possible to detect the pre- sence of mutated self-proteins (eg mutated oncogenes) or pro ⁇ teins derived from foreign infectious agents (eg. virus) whether they are based intra- or extra-cellularly.
  • mutated self-proteins eg mutated oncogenes
  • pro ⁇ teins derived from foreign infectious agents eg. virus
  • intracellularly based antigens which normally would escape antibody detection, can be detected using such "T cell-like" antibodies.
  • peptide-MHC specific antibodies have a diagnostic potential since they can identify - by way of example, but not limited to - tumor cells harbouring mutated oncogenes or infected cells harbouring virus's. Detection could be per- formed by fluoresence activated cell sorting (FACS, such as FACS Star from Becton Dickinson) which would allow detection, quantitation, characterization and purification of the cells of interest.
  • FACS fluoresence activated cell sorting
  • the peptide-MHC specific antibodies could also be attached to magnetic particles for high capacity cell sorting and purification of cells of interest.
  • ELISA's enzyme linked immunosorbent assays with the antigen coupled directly to micro- titer plates or via another antibody (the latter known as a sandwich technique) .
  • these soluble MHC mole ⁇ cules represents peptide-MHC complexes and that circulating soluble peptide-MHC complexes carries an imprint of the total intracellular protein metabolism of the body.
  • These specifi- cities can be accessed simply by taking a blood sample and making an ELISA using peptide-MHC specific antibodies for detection. This will have significant diagnostic implications since it will allow the intracellular metabolism be assessed using a blood sample.
  • T cell epitopes under conditions (e.g. immunoprecipitations, immuno histochemistry etc.) which precludes using T cells or recombinant soluble T cell receptor.
  • conditions e.g. immunoprecipitations, immuno histochemistry etc.
  • T cell epitopes on the antigen presenting cell may be visua ⁇ lized and quantified.
  • antibodies with peptide/MHC specificity might be useful in diagnostics since mutations or intracellular infections normally reserved for T cell recog ⁇ nition would be available to the antibodies, too. Diagnostic kits relating to the detection of specific T cell epitopes by the use of antibodies (or antibody fragments) are, therefore, dependent on the availability of the antibodies with the spe ⁇ cificity described in this invention.
  • the present invention provides a diagnostic composition for the detection of the presence of a peptide-MHC complex which comprises an antibody or antibody fragment, an anti-idiotypic antibody or an anti-anti-idiotypic antibody according to the invention.
  • the invention relates to a diagnos ⁇ tic composition for the detection of an intracellularly located pathogen selected from the group consisting of viruses, bacteria and parasites, to a diagnostic composition for the detection of a malignant tumour.
  • a human tumour antigens recognized by T-cells are known and may constitute useful targets for specific immunotherapy by use of the anti ⁇ bodies and antibody fragments of the invention.
  • the invention also relates to a diagnostic composition for the detection of the presence of an autoimmune disease and to a diagnostic composition for the asignment of individuals to high risk groups in relation to developing malignant tumours or autoimmune diseases.
  • a library of phages expressing immunoglobulin Fab fragments was panned on alternating matrices carrying Ha 255 _ 262 -MHC com ⁇ plexes as the only common denominator.
  • the first and third pannings were performed on Ha 255 . 2 g 2 loaded RMA-S-K k cells, and the second and the fourth pannings were performed on beads (Interfacial Dynamics, Oregon) coated with purified Ha 255 _ 262 -K k complexes.
  • Bound phages were eluted and amplified in E. coli after each panning round and analyzed by FACS for binding to peptide loaded RMA-S cells transfected with K k .
  • the peptides were Ha 255 . 2e2 (open bars) or NP 50 _ 57 (closed bars).
  • the black arrow indicates the background signal level.
  • Mean fluorescence intensity MFI.
  • RMA-S * K k cells were incubated overnight at 26°C with sub- optimal doses of Ha 255 . 262 or NP 50 _ 57 .
  • the peptide loaded RMA-S * K k cells were co-cultured with the Ha 255 _ 262 specific T cell hybridomas in the presence of graded doses of Fabl3.4.i.
  • the NP 50 _ 57 specific T cell hybridomas were co-cultured in the presence (black bars) or absence (white bars) of the maximum dose (390 nM) of Fabl3.4.1 (insert).
  • the suboptimal doses used were 6 ⁇ M Ha 255 .
  • Figure 5A shows that (in the case of the K k /Ha 255 . 2g2 library) 18 out of 20 individually selected clones after the 3rd round of panning bound to the antigen (K k /Ha 255 . 262 ) and that bind- ing was peptide specific in 16 out of these 20 clones. (That is, two out of the 20 clones bound to the K /Ha 255 . 262 antigen in a peptide non-specific manner) .
  • Figure 5B shows that (in the case of the K k /NP 50 _ 57 library) 7 out of 20 individually selected clones after the 3rd round of panning bound to the antigen (K k /NP 50 _ 57 ) and that binding was peptide specific in 1 out of these 20 clones.
  • the AKR derived lymphoma, RDM-4 was used for K k production as previously described (Olsen et al. , 1994). About lxlO 10 cells were resuspended in 100 ml of lysis buffer (PBS, 1% Nonidet P-40, 25 mM iodoacetamide, 1 mM PMSF (SIGMA, Cat. no. P-7626) , 5 mM sodium orthovanadate) and incubated for 10 mi- nutes at ambient temperature. The lysate was cleared by cen- trifugation, stored at -80°C and thawed by incubating over ⁇ night at +4°C before further use.
  • PBS 1% Nonidet P-40, 25 mM iodoacetamide, 1 mM PMSF (SIGMA, Cat. no. P-7626) , 5 mM sodium orthovanadate
  • the lysate was filtered several times through Millipore filters (from 8 to 0.45 ⁇ ) and the K k molecules were purified by affinity chromatography using the monoclonal anti K k antibody 11.4.1 (TIB95, obtained from the American Type Culture Collection, ATCC) .
  • the affin ⁇ ity column was prepared by covalently coupling of 11.4.1 to an activated cyanogen bromide Sephadex matrix as described by the manufacturer (Pharmacia) .
  • the lysate was passed over the column several times followed by extensive washing: (i) 20 column volumes of PBS, 0.1% SDS, 0.5 % Nonidet P-40, 0.02% sodium azide. (ii) 20 column volumes of PBS, 0.05% Nonidet P-40, 0.1% sodium azide. (iii) 20 column volumes of PBS, 0.1% sodium azide. Bound K k molecules were eluted with five column volumes (50 ml) of eluting buffer (0.05 M diethanolamine,
  • Human ⁇ 2-microglobulin was obtained from the urine of uraemic patients and purified to homogeneity by gel filtration and chromatofocusing (Stryhn et al., 1994).
  • Synesized manually on a RaMPS synthesizer (Dupont) using standard FMOC-protection strategy.
  • the reaction mixture contained 1 mM PMSF (Sigma, P-7626) , 8 mM ethylenediaminetetraacetic acid (EDTA) (BDH, 10093) , 1.2 mM 1.10 phenanthroline (Sigma, P-9375) , 69 ⁇ M pepstatin A (Sigma, P-4265) , 128 ⁇ M Na-p-tosyl-L-lysine chloromethyl ketone (TLCK) (Sigma, T-7254) , 135 ⁇ M Na-p- tosyl-L-phenylalanine chloromethyl ketone (TPCK) (Sigma,
  • Peptide-MHC complexes were generated as described above. Spin column chromatography was performed using a low detergent concentration (0.05% Nonidet P-40 in PBS) . Complexes in low detergent buffer were mixed with 1.5xl0 7 sulphurated latex beads (5 ⁇ in size, Interfacial Dynamics Corporation, Batch no. 436) and incubated overnight at +4°C with gentle shaking. The remaining sites on the beads were blocked with 1% bovine serum albumin in PBS. The beads were washed once and resus ⁇ pended in 1 ml of FACS buffer (1% BSA, PBS, 0.1% sodium azide) and used for either panning or FACS analysis. The bead preparations were stable for about one week at +4°C.
  • the RMA-S.K k cell line (donated by W. Ortiz-Navarette) is im ⁇ paired in the processing of MHC class I molecules due to the lack of peptide transporters which direct peptides from the cytoplasm to the endoplasmatic reticulum where endogenous peptide-MHC complexes are formed.
  • peptide transporters which direct peptides from the cytoplasm to the endoplasmatic reticulum where endogenous peptide-MHC complexes are formed.
  • K k By growing the cells in medium containing high concentration of peptide, almost full surface expression of K k can be achieved. Since this effect is a consequence of the peptide, most K k molecules will be complexed with the added peptide on the cell surface.
  • peptide loaded RMA-S.K k cells only express the desired peptide-MHC complex on their surface.
  • the complexes on the cell surface were formed by incubating IO 7 cells in 5 ml of growth media containing 0.1 mM peptide overnight at 26°C. Cells were harvested by centrifugation, washed once and resuspended in 1 ml of growth media.
  • Inbreed BALB/k mice were immunized i.p. with 1 Human Unit BCG (M. tuberculosis bovis, The State Serum Institute) .
  • BCG Human Unit BCG
  • 0.5 mg of K k in complex with HA 255 . 262 was mixed with 1 mg of PPD (supplied by The State Serum Institute) in a 0.1 mM phosphate buffer (pH 7.5) containing 0.05% Nonidet P-40.
  • First- strand cDNA was primed with oligo-dT n 18 using Superscript Plus (Gibco BRL) reverse transcriptase in a reaction mixture incubated at 42°C for one hour.
  • the cDNA template was ethanol precipi ⁇ tated and used for primary PCR amplifications of the VH, Fd and L-chain genes.
  • the primers used below are described in detail by ⁇ rum et al. , 1993.
  • PCR reactions were performed in 100 ⁇ l volumes containing dNTP's (0.2 mM) , reaction buffer supplied by the manufacturer (Cetus) , primers and cDNA.
  • VH reactions contained MVH 1-25 and 5 pmoles of each of the MJH 1-4 primers.
  • Fd reactions contained MVH 1-25 and 6.7 pmoles of each of the MCH yl, y2A and y2B primers.
  • L-chain reactions contained MVK 1-25 and 20 pmoles of the MCK primer. Reaction mixtures were overlaid with mineral oil and kept at 9 °C for 2 minutes.
  • DNA fragments from final assembly reactions were digested with NotI using 10 U per ⁇ g of D ⁇ A at 37°C for 2 hours. Following phenol extractions and ethanol precipitation, the D ⁇ A was dissolved in Sfil buffer and incubated under oil at 50°C for 2 hours with 10 U of enzyme per ⁇ g of D ⁇ A. The D ⁇ A was purified using GeneClean procedures and ligated to Gene- Clean-purified NotI and Sfil-cut pFAB5c. The 20 ⁇ l ligation reaction included 0.5 ⁇ g of digested vector, 0.5 ⁇ g of insert D ⁇ A and was incubated overnight at 15°C with 1.5 U of T 4 -D ⁇ A ligase (Amersham) .
  • the ligation mix was then purified by phenol extraction and ethanol precipitation followed by resu ⁇ spension in 20 ⁇ l of water. Portions of 2 ⁇ l were electropo ⁇ rated into E. coli TOP 10F' cells (British Biotechnology) using a Bio-Rad E. coli pulser set at 25 ⁇ F, 2.5 kV and 200 Ohms. Immediately after the pulse, one ml of freshly made SOC medium (Sambrook et al. , 1989) was added and the cells were shaken for one hour at 37°C. Serial dilutions were made and spread on LB-ampicillin plates to obtain an estimate of the size of the total library.
  • the VH and L-chain gene library consisted of 1.6xl0 7 clones and the Fd and L-chain gene library consisted of 6xlO ⁇ clones.
  • Each 1-ml transformation mixture was transferred to 40 ml of 2xTY medium containing 100 ⁇ g/ml ampicillin, 8 ⁇ g/ml tetracycline and 1% glucose. The cultures were incubated with shaking at 37°C until an OD 600 of 1-2 was reached. Aliquots of the libraries were made into glycerol stocks and stored at -80°C.
  • K k transfected RMA-S cells loaded with Ha 255 . 262 were prepared as described above. 80 ⁇ l of cells were mixed with 20 ⁇ l of phage library (about 10 11 cfu) and incubated at ambient temperature for three hours with gentle shaking. Cells were washed three times with growth media and bound phages were eluted by treatment with 1 mg/ml trypsin (Worthington) for one hour at 37°C. Cells were removed by centrifugation and the supernatant trans ⁇ ferred to vials containing 400 ⁇ l of exponentially growing E. coli TOP10F' cells (British Biotechnology) with an OD 600 of 0.8 to 1.0. The following superinfection was performed as described in the previous paragraph.
  • Ha 255 _ 2e2 -K k complexes were mixed with 20 ⁇ l of phage library (about 10 11 cfu) in 1% BSA, PBS buffer and incubated for three hours at +4°C with gentle shaking. Beads were precipi ⁇ tated by centrifugation and washed three times. Bound phages were eluted after the final wash by resuspending the beads in 100 ⁇ l of glycine elution buffer (0.1 M glycine-HCl, 0.1% BSA, pH 2.2) and were left for ten minutes at ambient tempe ⁇ rature.
  • glycine elution buffer 0.1 M glycine-HCl, 0.1% BSA, pH 2.2
  • FACS analysis was performed to evaluate Fab-phage binding to peptide pulsed RMA-S.K k cells or to detect binding of Fab fragments to various peptide-MHC combinations immobilized on beads.
  • FACS analysis using cells IO 5 RMA-S.K k cells pulsed with peptide were mixed with about 4 ⁇ l0 9 cfu Fab phages in 100 ⁇ l of FACS buffer (1% bovine serum albumin (BSA), PBS, 0.1% sodium azide) or with Fab 13.4.1 and incubated on ice for two hours followed by three rounds of washing with FACS buffer.
  • the detecting antibody was an FITC conjugated goat-anti-phage or rabbit antiM13-phage serum (both DAKO, Denmark) used in a 1:100 dilution in FACS buffer. The samples were incubated for 30 minutes on ice. Unbound antibodies were removed by washing and the remaining cells were resuspended in 200 ⁇ l of FACS buffer containing 1% formaldehyde and analyzed by FACS.
  • the FACS data were recorded using a FACScan (Becton Dickinson Immunocytometry) . Three parameters were collected for each analysis: (i) forward scattered light, (ii) side scattered light and (iii) the fluorescent emissions of fluorescein (515-545 nm) . A forward scatter threshold was set to exclude cell or bead debris. Data for 10 4 beads or cells were col- lected and analyzed using the Lysis II TM software (Becton Dickinson Immunocytometry) . Production and purification of soluble Fab fragments from selected clone:
  • Fab fragments of pSAN 13.4.1 were transferred to an expression vector which adds an HIS 6 -tag to the C-terminus of the light chain in place of the gene III element (Engberg et al. , 1995) .
  • Fab fragments were prepared as follows: two 2 1 flasks each containing 500 ml of 2xTY, 100 ⁇ g/ml ampicillin, 8 ⁇ g/ml tetracycline were inoculated with 10 ml of transformed cells and shaken at 37°C at 250 rpm. At an
  • OD 600 of 0.5 IPTG was added to a final concentration of 1 mM and incubation was continued for four hours at room tempera ⁇ ture with shaking (250 rpm) .
  • Periplasmic protein was isolated by resuspending the cells in 10 ml of ice-cold TES buffer (200 mM Tris-HCl, 5 mM EDTA (ethylene diamine tetra-acetic acid di-sodium salt di-hydrate) , 500 mM sucrose, pH 8.0) . After five minutes 15 ml of 1:4 TES buffer was added and the mixture incubated for 30 minutes on ice.
  • periplasmic fraction was dialysed against 4 1 of MES buffer (10 mM 2- [N-morpho- lino] ethanesulphonic acid (SIGMA, Cat. no. M-82-50) , 20 mM NaH 2 P0 4 , pH 5.6) overnight at 4°C.
  • MES buffer 10 mM 2- [N-morpho- lino] ethanesulphonic acid (SIGMA, Cat. no. M-82-50) , 20 mM NaH 2 P0 4 , pH 5.6) overnight at 4°C.
  • the periplasmic fraction was passed over ABx matrix (J.T. Baker Research Products) and retained material eluted using a gradient of 0.5 M NaH 2 P0 4 , pH 7.0.
  • Fab fragments were further purified by immobilized metal ion chromatography (IMAC) .
  • IMAC immobilized metal ion chromatography
  • the Fab-positive fractions from the ABx purification were adjusted to IMAC buffer A (PBS, 0.5 M NaCl) using a five times concentrated buffer stock and applied to a chelating Superose HR 10/2 column (Pharmacia Biosystems) which had been preloaded with 5 column volumes of 0.1 M CuS0 4 followed by column equilibration with buffer A.
  • Bound protein was eluted using a imidazole buffer (IMAC buffer A, 0.5 M imidazole) gradient (0 - 0.5 M) .
  • the amount of purified Fab fragments was estimated by SDS-PAGE and BCA assays. All purifications were performed on a High LoadTM system (Pharmacia Biosystems) . Generation of class I restricted mouse T cell hybridomas and cytotoxic T cell assays:
  • the K k transfected RMA-S cell line, RMA-S.K k (Stryhn et al., 1994) was incubated overnight at 26°C with Ha 255 . 262 ' or ⁇ p 5 o- 57 - After the incubation the cells were washed exten ⁇ sively and resuspended in culture media in varying concentra ⁇ tions of Fab 13.4.1.
  • IO 5 T hybridoma cells were incubated with 10 5 loaded RMA-S.K k cells for 24 hours at 37°C in a total of 250 ⁇ l and the supernatant tested for IL-2 release according to Kappler et al., 1981.
  • Syngenic animals were chosen to favour the generation of an antibody response directed against self-MHC restricted epito- pes and the BCG-PPD immunization regime originally described by Lachmann et al., 1978, was chosen for its efficiency.
  • Total spleen mRNA was isolated 10 days after the immunization and reverse transcribed to cDNA.
  • Specific sets of degenerate primers were used to PCR amplify the cDNA segments corre- sponding to the immunoglobulin Fab fragments and the frag ⁇ ments were subsequently cloned into the pFab5c vector ( ⁇ rum et al. , 1993) and expressed in fusion with the minor viral coat protein pill of the filamentous bacteriophage.
  • the initial library consisted of 2xl0 7 phages which were sub- jected to panning procedures followed by elution of bound phages and reamplification in E. coli .
  • phages were panned on K k transfected RMA-S cells (RMA-S * K k ) pulsed with Ha 255 . 262 , alternating with panning on Latex beads coated with purified homogeneous Ha 255 . 262 -K k complexes.
  • the purpose of the panning strategy was to change the matrix for every other panning round while maintaining a common selecting epitope, in casu Ha 255 . 62 -K k .
  • Reamplified phages from each round of selection were adjusted to 2xl0 10 cfu/ml and tested for binding to Ha 255 . 262 or NP 50 _ 57 pulsed RMA-S * K k cells by FACS analysis using FITC conjugated anti-phage antibodies as detecting antibody (the peptide NP 50 _ 57 peptide used for comparison is also K k -restricted) .
  • a maximal ⁇ sive enrichment for Ha 255 . 262 -K k recognizing Fab-phages was observed after the 2 x 2 alternating rounds of panning.
  • the approach used during the alternat ⁇ ing panning rounds was slightly different from the one already described: Instead of alternating between pannings on plastic surfaces coated with the selected MHC/peptide complex and cells expressing the same complex, the Fab-phage library (generated from K ⁇ /Ha 255 . 262 immunized mice) was panned on plastic surface coated with K k /Ha 255 . 262 complexes in the presence of competing amounts of Latex beads coated with K k - NP 50 _ 57 complexes.
  • the Fab-phage library generated from K k -NP 50 _ 57 immunized mice was panned on plastic coated K k -NP 50 _ 57 complexes in the presence of Latex beads coated with K k /Ha 255 . 257 complexes. It is anticipated that several versions of alternating panning strategies can be used suc ⁇ cessfully. Importantly, the applicability and generality of our immunization and alternating panning procedures have been demonstrated.
  • pSAN 13.4.1 recognizes complexes consisting of Ha 255 . 2S2 and K k in a way that appears reminiscent of a peptide-specific, MHC-restricted T cell specificity.
  • the pSAN 13.4.1-binding capacity of each of the single amino acid substituted analogs was determined in a biochemical assay, in which soluble analog-K k complexes were used to inhibit the binding of pSAN 13.4.1 to immobilized Ha 252 . 2g2 -K complexes.
  • the analog-K k complexes were generated under peptide-saturating conditions to minimize the influence of K k specificity and focus on the specificity of pSAN 13.4.1.
  • the most critical residue was T in position 4, which could only be replaced with the conservative substitution, S.
  • the second most critical residues were L in position 7 and S in position 3, where some substitutions, mostly conservative to semi-conservative, were accepted (data not shown) .
  • Less critical was F in position 1, which could be replaced by about 10 substitutions mostly conservative or semi-conserva ⁇ tive leading to less than a 10 fold loss in binding.
  • the less critical residues were G in position 5 and E in position 2, which could be replaced by 13-14 amino acids.
  • the least critical residue was I in position 8. which could be replaced with any other amino acid (except R) .
  • Fabl3.4.l was confirmed and the kinetics of the interaction were determined.
  • Purified Fabl3.4.1 was immobilized onto BIAcore sensor chips and challenged with preformed Ha 255 . 262 -K k or NP 50 . 57 -K k complexes.
  • Purified Fabl3.4.1 was diluted to 20 ⁇ g/ml in 10 mM acetate-buffer, pH 4.5 and coupled to the dextran surface of BIAcore chips by standard amine coupling chemistry according to the manufac ⁇ turer (Pharmacia, Sweden) .
  • Preformed complexes of K k and pep ⁇ tide were made as previously described.
  • concentration of formed complexes i.e. active binding sites of K k
  • trace amounts of iodinated NP 50 _ 57 with known specific activity was added during the formation of complex ⁇ es.
  • the amount of bound vs. free 1 5 I was determined by gamma counting, and the concentration of formed complexes calculated.
  • the amount of Fab fragment coupled to the chip was kept just below 1000 RU and the flow speed was set to 10 ⁇ l/minutes, thereby avoiding interference of mass transport limitations with the kinetic calculations. All measurements were done in 0.1% Nonidet P-40 and phosphate buffered saline at 22°C.
  • the sensorgrams demonstrate binding of Fabl3.4.l to Ha 255 . 262 -K k , but not to NP 50 - 57 - K k .
  • the K k specific monoclonal antibody, H100-27R55 supplied by Dr. G. Hammerling
  • Figure 3B illustrates that H100-27R55 bound both peptide-K k com ⁇ plexes equally well confirming that equal amounts of func ⁇ tional K k protein were available to the chips.
  • the sensorgrams of figure 3C revealed two experimental pro ⁇ blems: (i) a blank injection showed an increase in signal of about 19 RU and a nearly linear decrease to about 3 RU at the end of the association time, (ii) the base line declined about 1 RU/minute during the course of the experiments, indi ⁇ cating a slow loss of immobilized ligand. Both these experi ⁇ mental deviations were interpolated into straight lines and used to correct the association phases and the entire sensor- grams, respectively. These corrections and the following cal ⁇ culation were done using mathematical models developed by Ron Shymko, Hagedorn Research Laboratories, Gentofte, Denmark.
  • Fabl3.4.1 recognizes a Ha 255 . 262 -K k dependent epitope which is spatially or allosterically related to the epitope recognized by the T cell hybridomas HK8.3-5H3 and HK8.3-6F8.
  • concentration of Fabl3.4.1 needed to obtain inhibition of the two Ha 255 . 2g2 - specific, K k -restricted T cell hybridomas was as expected close to the K D measured by the BIAcore analysis.
  • these antibodies could mimick the function of killer T cells by directing toxins to cells harbouring intra ⁇ cellular targets such as virus or mutated oncogenes (tumour cells) thereby eradicating those cells.
  • These antibodies can be raised in experimental animals and subsequently "huma ⁇ nized", transferred to any isotype construct and be produced recombinant in large amounts; and they might be easier to administrate and control than T cells currently in use for adoptive immunotherapy.
  • the applicant requests that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been refused or withdrawn or is deemed to be withdrawn

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)

Abstract

L'invention concerne un procédé de production d'un anticorps ou d'un fragment d'anticorps reconnaissant spécifiquement un complexe de peptide-CMH. L'invention concerne également des anticorps et des fragments d'anticorps, lesquels sont conjugués à un agent pharmaceutique ou à un super antigène. De plus, l'invention concerne une composition pharmaceutique comprenant des anticorps ou des fragments d'anticorps, selon l'invention, destinés à la prévention ou au traitement de maladies infectieuses ou auto-immunes, ainsi que du cancer, et des compositions de diagnostic desdites maladies.
PCT/DK1996/000296 1995-06-30 1996-07-01 Anticorps recombines tires d'une banque de presentation de phage, contre un complexe peptide-cmh WO1997002342A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9504728A JPH11510375A (ja) 1995-06-30 1996-07-01 ペプチド−ｍｈｃ複合体を指向するファージディスプレイライブラリーからの組換え抗体
AU63535/96A AU6353596A (en) 1995-06-30 1996-07-01 Recombinant antibodies from a phage display library, directed against a peptide-mhc complex
EP96922777A EP0835306A1 (fr) 1995-06-30 1996-07-01 Anticorps recombines tires d'une banque de presentation de phage, contre un complexe peptide-cmh

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK77895 1995-06-30
DK0778/95 1995-06-30
DK1214/95 1995-10-30
DK121495 1995-10-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08981021 A-371-Of-International 1998-03-20
US09/957,113 Continuation US20020150914A1 (en) 1995-06-30 2001-09-19 Recombinant antibodies from a phage display library, directed against a peptide-MHC complex

Publications (1)

Publication Number Publication Date
WO1997002342A1 true WO1997002342A1 (fr) 1997-01-23

Family

ID=26064633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1996/000296 WO1997002342A1 (fr) 1995-06-30 1996-07-01 Anticorps recombines tires d'une banque de presentation de phage, contre un complexe peptide-cmh

Country Status (4)

Country Link
EP (1) EP0835306A1 (fr)
JP (1) JPH11510375A (fr)
AU (1) AU6353596A (fr)
WO (1) WO1997002342A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058693A1 (fr) * 1998-05-14 1999-11-18 Centre National De La Recherche Scientifique - Cnrs Complexe forme d'un peptide et d'un produit du complexe majeur d'histocompatibilite a la surface de phages
JP2001520397A (ja) * 1997-10-20 2001-10-30 ディバーシス リミテッド 種々のリガンドによるファージ提示ライブラリーのスクリーニング方法
US6447829B1 (en) 1999-03-10 2002-09-10 Good Humor - Breyers Ice Cream, Division Of Conopco, Inc. Ice confection
WO2002072142A2 (fr) * 2001-03-12 2002-09-19 Rijksuniversiteit Groningen Modulation d'un equilibre entre le systeme immunitaire de la muqueuse intestinale et la microflore intestinale
WO2003068201A2 (fr) * 2002-02-13 2003-08-21 Technion Research & Development Foundation Ltd. Anticorps presentant une specifite de type recepteur des lymphocytes t, une affinite encore superieure, et utilisation de celui-ci dans la detection et le traitement du cancer, d'infections virales et de maladies auto-immunes
WO2003070752A2 (fr) * 2002-02-20 2003-08-28 Dyax Corporation Ligands de liaison au complexe mhc-peptide
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2005116072A3 (fr) * 2004-05-27 2006-07-06 Jon A Weidanz Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation
US7632923B2 (en) * 2003-03-26 2009-12-15 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US8685893B2 (en) 1998-07-27 2014-04-01 Genentech, Inc. Phage display
US8747855B2 (en) 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
US10098951B2 (en) 2015-10-23 2018-10-16 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
EP3447075A2 (fr) 2015-05-15 2019-02-27 The General Hospital Corporation Anticorps antagonistes de la superfamille du récepteur du facteur de nécrose contre les tumeurs
WO2020061210A1 (fr) 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anticorps anti-tnfr2 et leurs utilisations
WO2020180712A1 (fr) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anticorps anti-tnfr2 et leurs utilisations
US10822413B2 (en) 2017-04-26 2020-11-03 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012332A1 (fr) * 1990-02-14 1991-08-22 Institut National De La Sante Et De La Recherche Medicale Anticorps monoclonaux reconnaissant un peptide associe a un antigene majeur d'histocompatibilite
WO1994029451A2 (fr) * 1993-06-16 1994-12-22 Celltech Limited Anticorps humanises
WO1995015982A2 (fr) * 1993-12-08 1995-06-15 Genzyme Corporation Procede de generation d'anticorps specifiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012332A1 (fr) * 1990-02-14 1991-08-22 Institut National De La Sante Et De La Recherche Medicale Anticorps monoclonaux reconnaissant un peptide associe a un antigene majeur d'histocompatibilite
WO1994029451A2 (fr) * 1993-06-16 1994-12-22 Celltech Limited Anticorps humanises
WO1995015982A2 (fr) * 1993-12-08 1995-06-15 Genzyme Corporation Procede de generation d'anticorps specifiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARKS, J.D. ET AL.: "Human antibody fragments specific for human blood group antigens from a phage display library", BIOTECHNOLOGY, vol. 11, October 1993 (1993-10-01), NEW YORK US, pages 1145 - 1149, XP002018879 *
WINTER, G.; MILSTEIN, C.: "Man-made antibodies", NATURE, vol. 349, 24 January 1991 (1991-01-24), LONDON GB, pages 293 - 299, XP000572614 *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520397A (ja) * 1997-10-20 2001-10-30 ディバーシス リミテッド 種々のリガンドによるファージ提示ライブラリーのスクリーニング方法
FR2778669A1 (fr) * 1998-05-14 1999-11-19 Centre Nat Rech Scient Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications
WO1999058693A1 (fr) * 1998-05-14 1999-11-18 Centre National De La Recherche Scientifique - Cnrs Complexe forme d'un peptide et d'un produit du complexe majeur d'histocompatibilite a la surface de phages
US8685893B2 (en) 1998-07-27 2014-04-01 Genentech, Inc. Phage display
US6447829B1 (en) 1999-03-10 2002-09-10 Good Humor - Breyers Ice Cream, Division Of Conopco, Inc. Ice confection
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US10407486B2 (en) 1999-11-15 2019-09-10 Miltenyi Biotech Gmbh Ligating BDCA-2 protein with BDCA-2 specific antibody for detecting or modulating dendritic cells
US8183039B2 (en) 1999-11-15 2012-05-22 Miltenyi Biotec Gmbh Method for isolating BDCA-4+ dendritic cells
US9095533B2 (en) * 2000-03-27 2015-08-04 Technion Research & Development Foundation Limited Antigen-presenting complex-binding compositions and uses thereof
US20110293616A1 (en) * 2000-03-27 2011-12-01 Technion Research & Development Foundation Ltd. Antigen-presenting complex-binding compositions and uses thereof
WO2002072142A2 (fr) * 2001-03-12 2002-09-19 Rijksuniversiteit Groningen Modulation d'un equilibre entre le systeme immunitaire de la muqueuse intestinale et la microflore intestinale
WO2002072142A3 (fr) * 2001-03-12 2003-03-20 Univ Groningen Modulation d'un equilibre entre le systeme immunitaire de la muqueuse intestinale et la microflore intestinale
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003208582B2 (en) * 2002-02-13 2007-12-06 Technion Research & Development Foundation Ltd. High affinity antibody having a TCR-like specificity and use in detection and treatment
AU2003208582C1 (en) * 2002-02-13 2008-08-07 Technion Research & Development Foundation Ltd. High affinity antibody having a TCR-like specificity and use in detection and treatment
WO2003068201A2 (fr) * 2002-02-13 2003-08-21 Technion Research & Development Foundation Ltd. Anticorps presentant une specifite de type recepteur des lymphocytes t, une affinite encore superieure, et utilisation de celui-ci dans la detection et le traitement du cancer, d'infections virales et de maladies auto-immunes
WO2003068201A3 (fr) * 2002-02-13 2003-12-04 Technion Res & Dev Foundation Anticorps presentant une specifite de type recepteur des lymphocytes t, une affinite encore superieure, et utilisation de celui-ci dans la detection et le traitement du cancer, d'infections virales et de maladies auto-immunes
EP2329814A1 (fr) * 2002-02-13 2011-06-08 Technion Research and Development Foundation, Ltd. Anticorps présentant une spécificité de type récepteur des lymphocytes T, une affinité encore supérieure et utilisation de celui-ci dans la détection et le traitement du cancer
AU2010214669B2 (en) * 2002-02-13 2012-01-12 Technion Research & Development Foundation Ltd. High Affinity Antibody Having a TCR-like Specificity and Use in Detection and Treatment
WO2003070752A3 (fr) * 2002-02-20 2004-04-15 Dyax Corp Ligands de liaison au complexe mhc-peptide
WO2003070752A2 (fr) * 2002-02-20 2003-08-28 Dyax Corporation Ligands de liaison au complexe mhc-peptide
US7718777B2 (en) 2002-02-20 2010-05-18 Technion Research & Development Foundation Ltd. MHC-peptide complex binding ligands
JP2005533486A (ja) * 2002-02-20 2005-11-10 ダイアックス、コープ Ｍｈｃ−ペプチド複合体結合リガンド
US20150118750A1 (en) * 2003-03-26 2015-04-30 Technion Research & Development Foundation Limited Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20100080805A1 (en) * 2003-03-26 2010-04-01 Technion Research & Development Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US9023348B2 (en) * 2003-03-26 2015-05-05 Technion Research & Development Foundation Limited Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US7638124B2 (en) * 2003-03-26 2009-12-29 Technion Research & Development Foundation Ltd. Antigen-presenting complex-binding compositions and uses thereof
US9616112B2 (en) 2003-03-26 2017-04-11 Technion Research & Development Foundation Limited Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US7632923B2 (en) * 2003-03-26 2009-12-15 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2005247950B2 (en) * 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2005116072A3 (fr) * 2004-05-27 2006-07-06 Jon A Weidanz Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation
US8747855B2 (en) 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
EP4292664A2 (fr) 2015-05-15 2023-12-20 The General Hospital Corporation Anticorps antagonistes de la superfamille du récepteur du facteur de nécrose contre les tumeurs
EP3447075A2 (fr) 2015-05-15 2019-02-27 The General Hospital Corporation Anticorps antagonistes de la superfamille du récepteur du facteur de nécrose contre les tumeurs
US10464988B2 (en) 2015-10-23 2019-11-05 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US10822389B2 (en) 2015-10-23 2020-11-03 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US11421013B2 (en) 2015-10-23 2022-08-23 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US10098951B2 (en) 2015-10-23 2018-10-16 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US11976105B2 (en) 2015-10-23 2024-05-07 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
US10822413B2 (en) 2017-04-26 2020-11-03 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
US11613573B2 (en) 2017-04-26 2023-03-28 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
US11965021B2 (en) 2017-04-26 2024-04-23 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
WO2020061210A1 (fr) 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anticorps anti-tnfr2 et leurs utilisations
WO2020180712A1 (fr) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anticorps anti-tnfr2 et leurs utilisations

Also Published As

Publication number Publication date
JPH11510375A (ja) 1999-09-14
AU6353596A (en) 1997-02-05
EP0835306A1 (fr) 1998-04-15

Similar Documents

Publication Publication Date Title
US20020150914A1 (en) Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
Andersen et al. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
EP0307434B1 (fr) Anticorps alteres
US8389016B2 (en) Use of a CD28 binding substance for making a pharmaceutical composition
JP3653093B2 (ja) 人化抗体
EP1835937B1 (fr) Compositions et procédés de traitement d'infections virales
WO1997002342A1 (fr) Anticorps recombines tires d'une banque de presentation de phage, contre un complexe peptide-cmh
Palmer et al. Selection of antibodies to cell surface determinants on mouse thymic epithelial cells using a phage display library
CN105377886A (zh) 识别mage-a1的高亲和力结合分子
JP2004537952A (ja) 多重特異的結合分子とその使用
JP2002531383A (ja) ヒト４−１ｂｂに特異的なヒト化抗体およびそれを含む医薬組成物
JPH10501267A (ja) 制限化ペプチド
US20230357396A1 (en) Monoclonal antibodies and methods for using same
JPH08501925A (ja) 糖蛋白ｐに対するモノクローナル抗体
AU777005B2 (en) Protein A based binding domains with desirable activities
Bjorkman et al. Model for the interaction of T-cell receptors with peptide/MHC complexes
AU706772B2 (en) Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
EP1404362B1 (fr) Peptide inhibiteurs bifonctionnels de signal-1/signal-2
AU705010B2 (en) Human antibodies to t-cell receptor peptides and methods for their preparation
CA2435672C (fr) Polypeptides capables de se lier aux cd64 et comprenant au moins un epitope de cellule t heterologue et leurs utilisations
Watkins et al. The isolation and characterisation of human monoclonal HLA‐A2 antibodies from an immune V gene phage display library
US7163686B1 (en) Protein A based binding domains with desirable activities
CN115947854A (zh) 抗人cd40蛋白单克隆抗体、制备方法及其应用
Rey et al. Characterization of human anti-acetylcholine receptor monoclonal autoantibodies from the peripheral blood of a myasthenia gravis patient using combinatorial libraries
US6613536B1 (en) Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BB BG BR BY CA CH CN CZ CZ DE DE DK DK EE EE ES FI FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996922777

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 504728

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996922777

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996922777

Country of ref document: EP